Male Breast Cancer Clinical Trial
Official title:
ETHAN: A Phase II Study Comparing Different Endocrine THerapies for mAle Breast caNcer
This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: - Tamoxifen - Anastrozole - Degarelix - Abemaciclib
Status | Recruiting |
Enrollment | 60 |
Est. completion date | April 1, 2036 |
Est. primary completion date | April 1, 2026 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Men aged 18 years or older, with diagnosis of invasive breast cancer who have not undergone surgical resection of the primary tumor and axillary nodes. - Stage I, II, or III per American Joint Committee on Cancer (AJCC) staging 8th edition (112). - Breast cancer must be hormone receptor-positive and HER2-negative according to definition below assessed by local pathology. - Hormone receptor-positive is defined as: positivity for at least one of the hormone receptors (estrogen receptor [ER] or progesterone receptor [PR]) by IHC. ER and PR assays are considered positive if there are > 1% positive tumor nuclei in the samples. - HER2-negative is defined per the current American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline (113). - Patients with multifocal or multicentric disease are eligible if the treating investigator has determined the patient should be treated as ER-positive and HER2-negative. - Bilateral breast cancers are allowed if the treating investigator has determined the patient should be treated as ER-positive and HER2-negative. - Patients with a history of ipsilateral or contralateral DCIS or LCIS are eligible. - ECOG performance status = 2. - Required laboratory values demonstrating adequate organ function: - ANC = 1000/mm3 - Hemoglobin = 8 g/dl - Platelets = 50,000/mm3 - Serum creatinine = 3.0 x ULN (institutional) - Total bilirubin = 2.0 x ULN (institutional). - AST and ALT = 5.0 x ULN (institutional) - Men with partners of childbearing potential must be willing to use one highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception by the patient and/or partner and continue its use for the duration of the study treatment and for 6 months after the last dose of study treatment. - Non-English-speaking patients are eligible but will be exempt from patient-completed questionnaires. - Willing and able to sign informed consent. - Willing to undergo breast biopsy after completion of window phase. - Patient is able to swallow oral medications. Exclusion Criteria: - Prior endocrine therapy, chemotherapy, radiation therapy, or investigational therapy for the current breast cancer diagnosis. - Prior endocrine therapy, systemic therapy, radiation therapy, or investigational therapy for any other malignancy within the past 12 months. - Diagnosis of inflammatory breast cancer (T4d). - Other concurrent serious diseases that may interfere with planned treatment, including severe cardiac disease, congestive heart failure (CHF) of New York Heart Association (NYHA) Class III or higher, severe pulmonary conditions/illness, uncontrolled infections. - The patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea). - The patient has active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment. - The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. |
Country | Name | City | State |
---|---|---|---|
United States | Dana Farber Cancer Institute | Boston | Massachusetts |
United States | M. D. Anderson Cancer Center at University of Texas | Houston | Texas |
United States | Mayo Clinic | Rochester | Minnesota |
United States | Georgetown University Medical Center | Washington | District of Columbia |
Lead Sponsor | Collaborator |
---|---|
Jose Pablo Leone | Eli Lilly and Company, Translational Breast Cancer Research Consortium (TBCRC) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Grade 3 or Higher Treatment-Related Toxicity Rate | All grade 3 or higher adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv5 as reported on case report forms were counted. Rate is the proportion of treated participants experiencing at least one treatment-related grade 3 or higher AE of any type during the time of observation. | Up to 6 months | |
Other | Trial enrollment | We will evaluate how many patients we are able to enroll to this trial in a period of 3 years | 3 years | |
Other | Trial completion | We will evaluate how many of the enrolled participants successfully complete the study protocol | 3 years | |
Other | EORTC QLC-C30 questionnaire | Patient-reported outcomes (PROs) measures will be conducted using the EORTC QLC-C30 questionnaire. | Up to 6 months | |
Other | Adapted EORTC BR23 questionnaire | Patient-reported outcomes (PROs) measures will be conducted using the EORTC BR23, adapted by replacing female-specific items with male-specific sexual activity/function items from PR25 (Appendix D of protocol) questionnaire. | Up to 6 months | |
Primary | Change in Ki-67 | Ki-67 will be evaluated by ImmunoHistoChemistry (IHC) following consensus recommendations using imaging analysis methods. | At the end of the 3-week window period. | |
Primary | RCB index | RCB will be determined using data from each participating institution pathology department, and will be reviewed by the study team pathologist. | At time of surgery. | |
Secondary | Changes in estradiol levels | To evaluate the physiologic endocrine changes that occur as a result of treatment with tamoxifen, anastrozole and anastrozole and degarelix as measured by estradiol levels at baseline and at the end of the three-week window period | Baseline and at the end of the three-week window period | |
Secondary | Changes in testosterone levels | To evaluate the physiologic endocrine changes that occur as a result of treatment with tamoxifen, anastrozole and anastrozole and degarelix as measured by testosterone levels at baseline and at the end of the three-week window period | Baseline and at the end of the three-week window period | |
Secondary | Preoperative Endocrine Prognostic Index (PEPI) score | To evaluate the comparative efficacy of the experimental treatments as measured by PEPI score at surgery. | At time of surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02480933 -
Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens
|
N/A | |
Terminated |
NCT01705340 -
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
|
Phase 1 | |
Terminated |
NCT01222377 -
Endoscopic Breast Surgery in Treating Patients With Breast Cancer
|
N/A | |
Completed |
NCT00244881 -
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
|
Phase 2 | |
Completed |
NCT00425672 -
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
|
Phase 1/Phase 2 | |
Completed |
NCT00096434 -
Sorafenib in Treating Patients With Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT01217411 -
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
|
Phase 1 | |
Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00791037 -
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00559507 -
Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00119262 -
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
|
Phase 2 | |
Completed |
NCT00098605 -
Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases
|
Phase 2 | |
Terminated |
NCT00095888 -
3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT00071942 -
Vaccine Therapy in Treating Patients With Metastatic Breast Cancer
|
Phase 1 | |
Completed |
NCT00068588 -
GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT01869764 -
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
|
Phase 2 | |
Completed |
NCT02046421 -
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 1 | |
Completed |
NCT01720602 -
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
|
N/A | |
Terminated |
NCT01931709 -
FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer
|
N/A | |
Completed |
NCT01493310 -
Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer
|
Phase 1 |